Tuesday, March 10, 2015 4:28:28 PM
GAITHERSBURG, Md., March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates.
Mr. Rosen comes to Novavax with over 20 years of industry and patient advocacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide. He previously developed and ran the Government Affairs, Policy and Alliance Development functions for MedImmune, which developed Synagis, a monoclonal antibody used to prevent RSV disease in premature newborns, and FluMist, a live attenuated influenza vaccine.
"The healthcare landscape is constantly changing and supportive vaccine policy requires diligent attention and coordination in concert with Novavax' commercialization plans. Brian's extensive experience, particularly with RSV and influenza, is critical to planning and executing a commercial launch of our vaccines," said John Trizzino, SVP, Commercial Operations. "Brian is a key addition to our management team and brings valuable perspective that I am confident will contribute to bringing our novel vaccines to market."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn
Senior Manager, Investor Relations
Novavax, Inc.
ir@novavax.com
240-268-2000
Recent NVAX News
- Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting • GlobeNewswire Inc. • 05/06/2024 10:22:33 AM
- Shah Capital nominates two highly qualified independent director candidates for Novavax • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
- Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:30:14 AM
- Novavax to Participate in TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/29/2024 09:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:07:50 PM
- Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 02/28/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:30:55 PM
- Goldman Sachs Reconsiders Fed Cuts, LUNR Surges Over 40% in Pre-Market, and More • IH Market News • 02/23/2024 01:03:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:02:36 AM
- Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement • PR Newswire (US) • 02/22/2024 11:00:00 AM
- Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024 • PR Newswire (US) • 02/20/2024 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:25:15 PM
- Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/03/2024 02:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:12:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:09:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:00:29 PM
- Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan • PR Newswire (US) • 12/18/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:00:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:00:16 PM
- Moderna Shares, Other Covid Vaccine Makers Hit by Warning From Pfizer • Dow Jones News • 12/13/2023 01:31:00 PM
- Canadians Can Help Protect Loved Ones as We Head into the Holiday Season • PR Newswire (Canada) • 12/13/2023 01:00:00 PM
- Novavax's Updated COVID-19 Vaccine Now Authorized in Canada • PR Newswire (US) • 12/05/2023 09:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM